Financhill
Sell
48

MBOT Quote, Financials, Valuation and Earnings

Last price:
$2.61
Seasonality move :
6.71%
Day range:
$2.56 - $2.73
52-week range:
$0.82 - $3.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.29x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
147.17%
Market cap:
$95.3M
Revenue:
--
EPS (TTM):
-$0.65

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MBOT
Microbot Medical
$1M -$0.08 -- -29.41% $9.00
CATX
Perspective Therapeutics
$162.9K -$0.31 -- -55.87% $14.1071
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$881K -$0.05 6.24% -40.63% $2.94
VTAK
Catheter Precision
$310K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.2M -$0.01 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MBOT
Microbot Medical
$2.62 $9.00 $95.3M -- $0.00 0% --
CATX
Perspective Therapeutics
$3.9800 $14.1071 $295.4M -- $0.00 0% 28.05x
RVP
Retractable Technologies
$0.68 -- $20.4M -- $0.00 0% 0.60x
VNRX
VolitionRX
$0.67 $2.94 $68.8M -- $0.00 0% 46.02x
VTAK
Catheter Precision
$0.24 -- $2.7M 0.40x $0.00 0% 2.77x
XTNT
Xtant Medical Holdings
$0.66 $1.75 $91.3M -- $0.00 0% 0.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MBOT
Microbot Medical
-- -0.516 -- --
CATX
Perspective Therapeutics
-- 1.363 -- --
RVP
Retractable Technologies
1.48% -0.677 12.06% 4.40x
VNRX
VolitionRX
-29.91% 3.387 11.38% 0.34x
VTAK
Catheter Precision
17.75% -1.532 53.57% 0.13x
XTNT
Xtant Medical Holdings
43.24% 1.491 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MBOT
Microbot Medical
-- -$3M -- -- -- -$2.9M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
RVP
Retractable Technologies
-$1.9K -$3.2M -25.99% -26.39% -122.86% -$1.6M
VNRX
VolitionRX
-- -$5.4M -- -- -2183.56% -$4.3M
VTAK
Catheter Precision
$132K -$3.5M -126.5% -137.84% -3300.7% -$2.3M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

Microbot Medical vs. Competitors

  • Which has Higher Returns MBOT or CATX?

    Perspective Therapeutics has a net margin of -- compared to Microbot Medical's net margin of --. Microbot Medical's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MBOT
    Microbot Medical
    -- -$0.08 --
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About MBOT or CATX?

    Microbot Medical has a consensus price target of $9.00, signalling upside risk potential of 243.51%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Perspective Therapeutics has higher upside potential than Microbot Medical, analysts believe Perspective Therapeutics is more attractive than Microbot Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    MBOT
    Microbot Medical
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is MBOT or CATX More Risky?

    Microbot Medical has a beta of 1.127, which suggesting that the stock is 12.737% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock MBOT or CATX?

    Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MBOT or CATX?

    Microbot Medical quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Microbot Medical's net income of -$2.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Microbot Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MBOT
    Microbot Medical
    -- -- -- -$2.6M
    CATX
    Perspective Therapeutics
    28.05x -- -- -$18.2M
  • Which has Higher Returns MBOT or RVP?

    Retractable Technologies has a net margin of -- compared to Microbot Medical's net margin of -126.59%. Microbot Medical's return on equity of -- beat Retractable Technologies's return on equity of -26.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    MBOT
    Microbot Medical
    -- -$0.08 --
    RVP
    Retractable Technologies
    -0.02% -$0.35 $77.8M
  • What do Analysts Say About MBOT or RVP?

    Microbot Medical has a consensus price target of $9.00, signalling upside risk potential of 243.51%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbot Medical has higher upside potential than Retractable Technologies, analysts believe Microbot Medical is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    MBOT
    Microbot Medical
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is MBOT or RVP More Risky?

    Microbot Medical has a beta of 1.127, which suggesting that the stock is 12.737% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

  • Which is a Better Dividend Stock MBOT or RVP?

    Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios MBOT or RVP?

    Microbot Medical quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $8.3M. Microbot Medical's net income of -$2.6M is higher than Retractable Technologies's net income of -$10.5M. Notably, Microbot Medical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 0.60x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MBOT
    Microbot Medical
    -- -- -- -$2.6M
    RVP
    Retractable Technologies
    0.60x -- $8.3M -$10.5M
  • Which has Higher Returns MBOT or VNRX?

    VolitionRX has a net margin of -- compared to Microbot Medical's net margin of -2201.34%. Microbot Medical's return on equity of -- beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MBOT
    Microbot Medical
    -- -$0.08 --
    VNRX
    VolitionRX
    -- -$0.06 -$22.6M
  • What do Analysts Say About MBOT or VNRX?

    Microbot Medical has a consensus price target of $9.00, signalling upside risk potential of 243.51%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 340.32%. Given that VolitionRX has higher upside potential than Microbot Medical, analysts believe VolitionRX is more attractive than Microbot Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    MBOT
    Microbot Medical
    0 0 0
    VNRX
    VolitionRX
    3 1 0
  • Is MBOT or VNRX More Risky?

    Microbot Medical has a beta of 1.127, which suggesting that the stock is 12.737% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

  • Which is a Better Dividend Stock MBOT or VNRX?

    Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MBOT or VNRX?

    Microbot Medical quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Microbot Medical's net income of -$2.6M is higher than VolitionRX's net income of -$5.4M. Notably, Microbot Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 46.02x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MBOT
    Microbot Medical
    -- -- -- -$2.6M
    VNRX
    VolitionRX
    46.02x -- $246.4K -$5.4M
  • Which has Higher Returns MBOT or VTAK?

    Catheter Precision has a net margin of -- compared to Microbot Medical's net margin of -2828.67%. Microbot Medical's return on equity of -- beat Catheter Precision's return on equity of -137.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    MBOT
    Microbot Medical
    -- -$0.08 --
    VTAK
    Catheter Precision
    92.31% -$0.36 $9.6M
  • What do Analysts Say About MBOT or VTAK?

    Microbot Medical has a consensus price target of $9.00, signalling upside risk potential of 243.51%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 727.82%. Given that Catheter Precision has higher upside potential than Microbot Medical, analysts believe Catheter Precision is more attractive than Microbot Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    MBOT
    Microbot Medical
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is MBOT or VTAK More Risky?

    Microbot Medical has a beta of 1.127, which suggesting that the stock is 12.737% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

  • Which is a Better Dividend Stock MBOT or VTAK?

    Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MBOT or VTAK?

    Microbot Medical quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $143K. Microbot Medical's net income of -$2.6M is higher than Catheter Precision's net income of -$4M. Notably, Microbot Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 2.77x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MBOT
    Microbot Medical
    -- -- -- -$2.6M
    VTAK
    Catheter Precision
    2.77x 0.40x $143K -$4M
  • Which has Higher Returns MBOT or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Microbot Medical's net margin of 0.18%. Microbot Medical's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    MBOT
    Microbot Medical
    -- -$0.08 --
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About MBOT or XTNT?

    Microbot Medical has a consensus price target of $9.00, signalling upside risk potential of 243.51%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that Microbot Medical has higher upside potential than Xtant Medical Holdings, analysts believe Microbot Medical is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    MBOT
    Microbot Medical
    0 0 0
    XTNT
    Xtant Medical Holdings
    1 0 1
  • Is MBOT or XTNT More Risky?

    Microbot Medical has a beta of 1.127, which suggesting that the stock is 12.737% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

  • Which is a Better Dividend Stock MBOT or XTNT?

    Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MBOT or XTNT?

    Microbot Medical quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Microbot Medical's net income of -$2.6M is lower than Xtant Medical Holdings's net income of $58K. Notably, Microbot Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MBOT
    Microbot Medical
    -- -- -- -$2.6M
    XTNT
    Xtant Medical Holdings
    0.73x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock